• InMed Pharmaceuticals plans a 1-for-10 share consolidation in connection with its proposed merger with Mentari Therapeutics.
• Completion is expected after market close November 4, 2026, conditional on shareholder approval of three merger-related proposals at that day's meeting.
• Outstanding Common Shares would fall from 5,493,735 to approximately 549,374 before the merger.
• Consolidation-adjusted trading on the Nasdaq Capital Market is expected to begin at market open November 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202611021615NEWSFILECNPR____20261102_322094_1) on November 02, 2026, and is solely responsible for the information contained therein.